Attitudes of patients and family members towards implantable psychiatric medication.
BACKGROUND
Medication is a necessary part of treatment for severe psychiatric illnesses such as schizophrenia and nonadherence to prescribed medication is one of the most important public health issues in psychiatry today. The devastating consequences of nonadherence have motivated the development of novel therapeutic strategies, including a new long-term implantable medication delivery system.


METHODS
The current study assesses attitudes towards implantable medication in psychiatric patients and their family members. Patients included in the study had diagnoses of Schizophrenia, Schizoaffective Disorder, Mood or Anxiety related disorders.


RESULTS
49.62% of patients and 74.47% of family members endorse support for implantable medication.


CONCLUSIONS
This study demonstrates that implants may be an acceptable alternative to oral and injectable medication for a subset of psychiatric patients and their families.
Dankert
Mary E
ME
Stanley Center for Experimental Therapeutics in Psychiatry, Division of Neuropsychiatry, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, United States.
Brensinger
Colleen M
CM
Metzger
Kayla L
KL
Li
Chunbo
C
Koleva
Svetlinka G
SG
Mesén
Andrea
A
Laprade
Béatrice
B
Wiguna
Tjhin
T
Han
Changsu
C
Farooq
Saeed
S
Severus
W Emanuel
WE
Gayares
Jocelyn G
JG
Langosch
Jens M
JM
Lallart
Xavier
X
Tateno
Masaru
M
Mihai
Adriana
A
Nair
Sudha R N
SR
Belmaker
Robert
R
Rybakowski
Janusz
J
Owe-Larsson
Björn
B
Kane
John M
JM
Johnstone
Eve C
EC
MacIntyre
Donald J
DJ
Malhotra
Sameer
S
González-Pinto
Ana
A
Mosquera
Fernando
F
Babb
Suzann M
SM
Habib pour
Ehsan
E
Fatemi
Seyedeh Sedigheh
SS
Swanson
Charles
C
Adler
Caleb
C
Young
Allan
A
Hoeft
Fumiko
F
Sivakumar
Kandiah
K
Radoeva
Petya D
PD
Lallart
Elise A
EA
Bilker
Warren B
WB
Siegel
Steven J
SJ
D000328:Adult; D001294:Attitude to Health; D003024:Clozapine / Q000008:administration & dosage / Q000627:therapeutic use; D003431:Cross-Cultural Comparison; D003625:Data Collection / Q000706:statistics & numerical data; D004343:Drug Implants / Q000008:administration & dosage / Q000627:therapeutic use*; D005190:Family / Q000523:psychology*; D005260:Female; D006220:Haloperidol / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy* / Q000523:psychology*; D008875:Middle Aged; D019964:Mood Disorders / Q000188:drug therapy / Q000523:psychology; D010349:Patient Compliance; D011618:Psychotic Disorders / Q000188:drug therapy / Q000523:psychology; D011619:Psychotropic Drugs / Q000008:administration & dosage / Q000627:therapeutic use*; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy; D012565:Schizophrenic Psychology; D016896:Treatment Outcome; D014481:United States
D004343:Drug Implants; D011619:Psychotropic Drugs; D003024:Clozapine; D006220:Haloperidol